Carcinoid Syndrome
Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors
October 23, 2017Results of the double-blinded and initial open-label phases of the ELECT Study demonstrate the effectiveness of lanreotide in controlling diarrhea and flushing in patients with NETs presenting with carcinoid syndrome.
Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
September 25, 2017Development of carcinoid syndrome has a profound effect on cost of care for patients with neuroendocrine tumors (NETs).
FDA Approves Supplemental Indication for Lanreotide Depot for Carcinoid Syndrome
September 19, 2017Patients who receieved lanreotide depot had a significantly lower percentage of days when rescue octreotide was used compared with placebo.
Lanreotide Eases Carcinoid Syndrome Symptoms in All Patients
June 04, 2017Lanreotide decreased the proportion of days patients had flushing and diarrhea compared with placebo, even in patients previously responsive to rescue therapy with octreotide.
Sign Up for Free e-newsletters
ONA Articles
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
- In Older Women With Breast Cancer QoL May Predict 10-Year Mortality
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
- Support for Exercise Programs During, After Cancer Treatment
- Oncology Clinicians Disagree on School Attendance for Children With Cancer
- False-Positive Cancer Screening Results May Increase Likelihood of Future Screenings
- Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |